Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

Patients using GLP-1 drugs had no difference in the odds of postoperative aspiration pneumonia versus non-users. Preoperative ...

South Africa's Aspen Pharmacare has started registering GLP-1 drugs used to treat diabetes and obesity in markets where ...

In recent years, the growing list of medical benefits for GIP and GLP-1 agonists (think Ozempic for diabetes or Zepbound for ...

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

A boost for the category, and perhaps even a change in the way products are marketed, is anticipated based on research ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

Weight-loss drugs are changing the way people grocery shop and eat. But those spending habits don't necessarily last.

This month pharmacies will no longer be allowed to sell lower-cost compounded versions of the anti-obesity drug tirzepatide — ...

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

A product development expert explains how the swift rise of these anti-obesity medications is fueling new food trends.

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.